JAK Monotherapy Shows Efficacy in RA Review
A systematic review found Janus kinase inhibitor monotherapy improved outcomes vs methotrexate or placebo, but direct comparisons with combination therapy were limited.
By
Andrea Surnit
May 22, 2026
Clinical Scorecard: JAK Monotherapy Shows Efficacy in RA Review
At a Glance
Category Detail
Condition Key Mechanisms Janus kinase inhibitors (JAKi) are associated with improved clinical, functional, and radiographic outcomes. Target Population Care Setting
Key Highlights
Remove unsupported phrases and ensure all claims are directly sourced. Guideline-Based Recommendations
Diagnosis
Management
Combination therapy with conventional synthetic DMARDs is generally favored, but monotherapy is allowed for patients who cannot tolerate methotrexate. Monitoring & Follow-up
Risks
Patient & Prescribing Data
JAKi monotherapy is reported as effective and generally well-tolerated, but safety concerns should be considered.
Clinical Best Practices
Conduct individualized assessments for treatment options. Evaluate patient history for cardiovascular risks before initiating JAKi therapy. Ensure regular follow-up to monitor treatment response and adverse events. Related Resources & Content
